RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.